中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 42-49

Guidelines on the diagnosis and management of autoimmune hepatitis (2021)

DOI: 10.3760/cma.j.cn112138-20211112-00796
  • Received Date: 2021-12-25
  • Published Date: 2022-01-20
    Abstract
  • Autoimmune hepatitis (AIH) is characterized by elevated serum aminotransferase and immunoglobulin G levels, seropositive results for autoantibodies and moderate to severe interface hepatitis in histologic findings. It will be most helpful in improving survival and life quality, if patients are diagnosed in the early stage and treated appropriately, which also helps relieve social medical burdens. Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015) has contributed to standardizing the diagnosis and treatment of AIH. On the basis of the first consensus, at the end of 2021, under the organization of Chinese Society of Hepatology, experts devise this guide with latest advances aiming to further improve the level of diagnosis and management of autoimmune hepatitis.

     

    • FullText(HTML)
  • 志谢(以姓氏拼音排序): 安纪红(内蒙古自治区人民医院感染科)、邓国宏(陆军军医大学第一附属医院传染科)、黄燕(中南大学湘雅医院传染科)、黄缘(北京清华长庚医院肝胆内科)、李荣宽(大连医科大学附属二院感染科)、李树臣(哈尔滨医科大学第二附属医院传染科)、陆海英(北京大学第一医院传染科)、石荔(西藏自治区人民医院感染科)、苏明华(广西医科大学第一附属医院感染科)、温志立(南昌大学第二附属医院消化内科)、吴彪(海南省人民医院感染科)、徐京杭(北京大学第一医院肝病科)、杨丽(四川大学华西医院消化内科)、杨积明(天津市第二人民医院感染科)、杨晋辉(昆明医科大学附属二院消化内科)、张缭云(山西医科大学第一医院传染科)、周璐(天津医科大学总医院消化内科)、周永健(广州市第一人民医院消化内科)、祖红梅(青海省第四人民医院传染科)参加本指南制定的讨论, 并提出了富有建设性的意见和建议。
    • References(47)
  • [1]
    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2016, 32(1): 9-22. DOI: 10.3969/j.issn.1001-5256.2016.01.002.
    [2]
    de BOER YS, GERUSSI A, van den BRAND FF, et al. Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2019, 17(8): 1616-1624. e2. DOI: 10.1016/j.cgh.2018.11.028.
    [3]
    WANG QX, YAN L, MA X. Autoimmune hepatitis in the Asia-Pacific Area[J]. J Clin Transl Hepatol, 2018, 6(1): 48-56. DOI: 10.14218/JCTH.2017.00032.
    [4]
    LAMBA M, NGU JH, STEDMAN C. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(3): 573-579. e1. DOI: 10.1016/j.cgh.2020.05.061.
    [5]
    TANAKA A, MORI M, MATSUMOTO K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan[J]. Hepatol Res, 2019, 49(8): 881-889. DOI: 10.1111/hepr.13342.
    [6]
    TANAKA A. Autoimmune Hepatitis: 2019 Update[J]. Gut Liver, 2020, 14(4): 430-438. DOI: 10.5009/gnl19261.
    [7]
    LI Y, YAN L, WANG R, et al. Serum immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis type 1: A single-center experience and literature review[J]. Clin Rev Allergy Immunol, 2021. DOI: 10.1007/s12016-021-08833-w.[Online ahead of print]
    [8]
    WANG QX, JIANG WJ, MIAO Q, et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: A single center experience[J]. J Dig Dis, 2013, 14(4): 175-180. DOI: 10.1111/1751-2980.12022.
    [9]
    DHALIWAL HK, HOEROLDT BS, DUBE AK, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis[J]. Am J Gastroenterol, 2015, 110(7): 993-999. DOI: 10.1038/ajg.2015.139.
    [10]
    GURUNG A, ASSIS DN, MCCARTY TR, et al. Histologic features of autoimmune hepatitis: A critical appraisal[J]. Hum Pathol, 2018, 82: 51-60. DOI: 10.1016/j.humpath.2018.07.014.
    [11]
    MIAO Q, BIAN Z, TANG R, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 226-235. DOI: 10.1007/s12016-014-8432-0.
    [12]
    STRAVITZ RT, LEFKOWITCH JH, FONTANA RJ, et al. Autoimmune acute liver failure: Proposed clinical and histological criteria[J]. Hepatology, 2011, 53(2): 517-526. DOI: 10.1002/hep.24080
    [13]
    TAKAHASHI A, ARINAGA-HINO T, OHIRA H, et al. Autoimmune hepatitis in Japan: Trends in a nationwide survey[J]. J Gastroenterol, 2017, 52(5): 631-640. DOI: 10.1007/s00535-016-1267-0.
    [14]
    ALVAREZ F, BERG PA, BIANCHI FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
    [15]
    HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
    [16]
    QIU D, WANG Q, WANG H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients[J]. J Hepatol, 2011, 54(2): 340-347. DOI: 10.1016/j.jhep.2010.06.032.
    [17]
    GALASKI J, WEILER-NORMANN C, SCHAKAT M, et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing[J]. J Hepatol, 2021, 74(2): 312-320. DOI: 10.1016/j.jhep.2020.07.032.
    [18]
    CHEN RL, WANG QX, MA X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis, 2019, 20(7): 331-337. DOI: 10.1111/1751-2980.12786.
    [19]
    WANG Z, SHENG L, YANG Y, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: Real-world experience and a comprehensive review[J]. Clin Rev Allergy Immunol, 2017, 52(3): 424-435. DOI: 10.1007/s12016-016-8583-2.
    [20]
    PEISELER M, LIEBSCHER T, SEBODE M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 260-267. e1. DOI: 10.1016/j.cgh.2016.12.040.
    [21]
    MANNS MP, WOYNAROWSKI M, KREISEL W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J]. Gastroenterology, 2010, 139(4): 1198-1206. DOI: 10.1053/j.gastro.2010.06.046.
    [22]
    WOYNAROWSKI M, NEMETH A, BARUCH Y, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents[J]. J Pediatr, 2013, 163(5): 1347-1353. e1. DOI: 10.1016/j.jpeds.2013.05.042.
    [23]
    EFE C, HAGSTRÖM H, YTTING H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15(12): 1950-1956. e1. DOI: 10.1016/j.cgh.2017.06.001.
    [24]
    LIBERAL R, de BOER YS, ANDRADE RJ, et al. Expert clinical management of autoimmune hepatitis in the real world[J]. Aliment Pharmacol Ther, 2017, 45(5): 723-732. DOI: 10.1111/apt.13907.
    [25]
    DE LEMOS-BONOTTO M, VALLE-TOVO C, COSTABEBER AM, et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J]. Eur J Gastroenterol Hepatol, 2018, 30(2): 212-216. DOI: 10.1097/MEG.0000000000001019.
    [26]
    HANOUNEH M, RITCHIE MM, ASCHA M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol, 2019, 54(1): 76-80. DOI: 10.1080/00365521.2018.1551498.
    [27]
    MONTANO-LOZA AJ, BHANJI RA, WASILENKO S, et al. Systematic review: Recurrent autoimmune liver diseases after liver transplantation[J]. Aliment Pharmacol Ther, 2017, 45(4): 485-500. DOI: 10.1111/apt.13894.
    [28]
    MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
    [29]
    KERKAR N, YANNI G. 'De novo' and 'recurrent' autoimmune hepatitis after liver transplantation: A comprehensive review[J]. J Autoimmun, 2016, 66: 17-24. DOI: 10.1016/j.jaut.2015.08.017.
    [30]
    MORIYAMA T, NISHⅡ R, PEREZ-ANDREU V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity[J]. Nat Genet, 2016, 48(4): 367-373. DOI: 10.1038/ng.3508.
    [31]
    LOHSE AW, SEBODE M, J∅RGENSEN MH, et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group[J]. J Hepatol, 2020, 73(6): 1496-1506. DOI: 10.1016/j.jhep.2020.07.023.
    [32]
    XU Q, SHENG L, BAO H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2017, 32(3): 639-644. DOI: 10.1111/jgh.13508.
    [33]
    HARTL J, EHLKEN H, SEBODE M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol, 2018, 68(4): 754-763. DOI: 10.1016/j.jhep.2017.11.020.
    [34]
    FIX OK, BLUMBERG EA, CHANG KM, et al. American Association for the Study of Liver Diseases Expert Panel consensus statement: Vaccines to prevent coronavirus disease 2019 infection in patients with liver disease[J]. Hepatology, 2021, 74(2): 1049-1064. DOI: 10.1002/hep.31751.
    [35]
    CORNBERG M, BUTI M, EBERHARDT CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients[J]. J Hepatol, 2021, 74(4): 944-951. DOI: 10.1016/j.jhep.2021.01.032.
    [36]
    BIEWENGA M, INDERSON A, TUSHUIZEN ME, et al. Early predictors of short-term prognosis in acute and acute severe autoimmune hepatitis[J]. Liver Transpl, 2020, 26(12): 1573-1581. DOI: 10.1002/lt.25906.
    [37]
    ZACHOU K, ARVANITI P, AZARIADIS K, et al. Prompt initiation of high-dose i. v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis[J]. Hepatol Res, 2019, 49(1): 96-104. DOI: 10.1111/hepr.13252.
    [38]
    YEOMAN AD, WESTBROOK RH, ZEN Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome[J]. J Hepatol, 2014, 61(4): 876-882. DOI: 10.1016/j.jhep.2014.05.021.
    [39]
    REDDY HG, SCHNEIDER BJ, TAI AW. Immune checkpoint inhibitor-associated colitis and hepatitis[J]. Clin Transl Gastroenterol, 2018, 9(9): 180. DOI: 10.1038/s41424-018-0049-9.
    [40]
    CZAJA AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis[J]. Autoimmunity, 2019, 52(4): 144-160. DOI: 10.1080/08916934.2019.1641200.
    [41]
    LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
    [42]
    LIN XQ, SHENG L, XIAO X, et al. Analysis of clinical diagnosis and treatment in chronic hepatitis B combined with autoimmune hepatitis[J]. Chin J Hepatol, 2020, 28(4): 351-356. DOI: 10.3760/cma.j.cn501113-20190120-00020.

    林小钦, 盛黎, 肖潇, 等. 慢性乙型肝炎合并自身免疫性肝炎的临床诊治分析[J]. 中华肝脏病杂志, 2020, 28(4): 351-356. DOI: 10.3760/cma.j.cn501113-20190120-00020.
    [43]
    MIELI-VERGANI G, VERGANI D, BAUMANN U, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement[J]. J Pediatr Gastroenterol Nutr, 2018, 66(2): 345-360. DOI: 10.1097/MPG.0000000000001801.
    [44]
    NASTASIO S, SCIVERES M, MATARAZZO L, et al. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine[J]. Dig Liver Dis, 2019, 51(5): 712-718. DOI: 10.1016/j.dld.2018.10.018.
    [45]
    EFE C, TAⅡ HA, YTTING H, et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci, 2018, 63(5): 1348-1354. DOI: 10.1007/s10620-018-5011-x.
    [46]
    WANG Q, QIU D, MA X. Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients[J]. Aliment Pharmacol Ther, 2011, 34(1): 107-109. DOI: 10.1111/j.1365-2036.2011.04690.x.
    [47]
    TANSEL A, KATZ LH, EL-SERAG HB, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: A systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217. e4. DOI: 10.1016/j.cgh.2017.02.006.
    • Relative Articles

  • Relative Articles

    [1]Lichen LI, Shaohui TANG. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome with gastric adenocarcinoma: A case report[J]. Journal of Clinical Hepatology, 2023, 39(5): 1150-1153. doi: 10.3969/j.issn.1001-5256.2023.05.022
    [2]Li WANG, Yongfeng YANG. Diagnosis and treatment of autoimmune hepatitis: The indispensable role of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 504-510. doi: 10.3969/j.issn.1001-5256.2023.03.004
    [3]Xuexin WANG, Yingxia LI, Libin JIANG, Mingxia ZHOU, Dapeng WEI, Xiaopeng ZHANG, Hongtao WEN. Diagnostic value of real-time shear wave elastography for liver fibrosis in patients with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2023, 39(1): 97-103. doi: 10.3969/j.issn.1001-5256.2023.01.015
    [4]Shangjuan YAO, Yilin LI, Mingjie CHEN, Qiang LI. Advances in the diagnosis and treatment of autoimmune liver disease overlap syndrome[J]. Journal of Clinical Hepatology, 2023, 39(8): 1952-1957. doi: 10.3969/j.issn.1001-5256.2023.08.028
    [5]Huaie LIU, Jiandan QIAN, Chi ZHANG, Yiqi LIU, Zhi LI, Hong ZHAO, Guiqiang WANG. Role of new noninvasive methods in guiding the diagnosis and treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2022, 38(4): 908-912. doi: 10.3969/j.issn.1001-5256.2022.04.034
    [6]Weiwei JU, Wanqian LI, Xiaojuan XIN, Tao JIANG. A case of autoimmune hepatitis presenting as acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(3): 629-631. doi: 10.3969/j.issn.1001-5256.2022.03.025
    [7]Lin HAN, Mingyue ZHANG, Ying SUN. Role of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain in the immune mechanism of autoimmune hepatitis and its prospects in treatment[J]. Journal of Clinical Hepatology, 2022, 38(3): 656-659. doi: 10.3969/j.issn.1001-5256.2022.03.034
    [8]Mengting ZHOU, Hongmei HAN. A diagnosis of atypical autoimmune hepatitis: A case report[J]. Journal of Clinical Hepatology, 2022, 38(11): 2565-2567. doi: 10.3969/j.issn.1001-5256.2022.11.024
    [9]Chinese Society of Hepatology. Guidelines on the diagnosis and management of primary biliary cholangitis (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 35-41. doi: 10.3760/cma.j.cn112138-20211112-00794
    [10]Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 50-61. doi: 10.3760/cma.j.cn112138-20211109-00786
    [11]Wendi DONG, Hairong ZHANG, Rui LI, Yuyan ZHANG, Jie ZHU. Role of regulatory T/T helper 17 cells in the pathogenesis of autoimmune hepatitis and related therapeutic targets[J]. Journal of Clinical Hepatology, 2021, 37(10): 2456-2460. doi: 10.3969/j.issn.1001-5256.2021.10.042
    [12]Mingyue ZHANG, Lin HAN, Ying SUN, Zhengsheng ZOU. Research advances in clinical treatment of adult autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1459-1465. doi: 10.3969/j.issn.1001-5256.2021.06.050
    [13]Lyu JiaYu, Han Tao. An excerpt of hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2018)[J]. Journal of Clinical Hepatology, 2019, 35(4): 766-768. doi: 10.3969/j.issn.1001-5256.2019.04.012
    [14]Fang Dan, Chen ZheYu. Diagnosis and treatment of hepatic alveolar echinococcosis[J]. Journal of Clinical Hepatology, 2017, 33(5): 990-993. doi: 10.3969/j.issn.1001-5256.2017.05.042
    [15]Ding HuiGuo, Zhang ShiBin, Li Lei, Li Peng, Zhang YueNing, Wang ZhenBiao. Endoscopic diagnosis and treatment of esophageal and gastric varices in patients with liver cirrhosis:from guidelines to clinical practice[J]. Journal of Clinical Hepatology, 2017, 33(3): 454-457. doi: 10.3969/j.issn.1001-5256.2017.03.011
    [16]Biliary Surgery Group of Surgery Branch of Chinese Medical Association. Guideline for the diagnosis and treatment of gallbladder carcinoma(2015 edition)[J]. Journal of Clinical Hepatology, 2016, 32(3): 411-419. doi: 10.3969/j.issn.1001-5256.2016.03.002
    [17]Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. Journal of Clinical Hepatology, 2016, 32(1): 9-22. doi: 10.3969/j.issn.1001-5256.2016.01.002
    [18]Liu Yan, Huang ZhiHua. Clinical diagnosis and treatment of cholestatic hepatopathy in infants[J]. Journal of Clinical Hepatology, 2015, 31(8): 1218-1220. doi: 10.3969/j.issn.1001-5256.2015.08.009
    [19]Wang QianYi, Jia JiDong. Advances in diagnosis and treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2015, 31(2): 160-162. doi: 10.3969/j.issn.1001-5256.2015.02.003
    [20]Zhao Ning, Li ZhiWei. Diagnosis and treatment of acute hepatitis C[J]. Journal of Clinical Hepatology, 2014, 30(6): 489-492. doi: 10.3969/j.issn.1001-5256.2014.06.003
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(80)

    1. 孙大沙，王晗，田家华，吴楠，王海强. 中医药调控NF-κB及Nrf2通路干预自身免疫性肝炎的研究进展. 中医药学报. 2025(02): 115-122 .
    2. 张文君，夏江，王昊，杨硕，刘婷，朱婷. 姜黄素对肝损伤的改善作用及其机制研究进展. 中国医院药学杂志. 2025(01): 99-107 .
    3. 崔健娇，张丽慧，刘光伟. 刘光伟运用引火汤加减治疗自身免疫性肝炎经验总结. 中西医结合肝病杂志. 2025(01): 93-95 .
    4. 丘永芳，邱梅花，邱小辉. 熊去氧胆酸联合糖皮质激素对自身免疫性肝炎患者肝功能及外周血CD4~+、CD8~+水平的影响. 天津药学. 2025(01): 44-47 .
    5. 陆雨佳，区可滢，马越洋，袁传溯，刘斌，杨永峰，熊清芳. UGT1A1多态性与UGT1A1抑制药物相关药物性肝损伤的关系. 实用医学杂志. 2025(04): 588-593 .
    6. 孙岩，吕冠华，范颖. 基于“肝与大肠相通”探讨从肠道菌群论治自身免疫性肝病. 中西医结合肝病杂志. 2025(02): 234-237 .
    7. 辛意，徐春军. 徐春军教授治疗自身免疫性肝炎的经验浅析. 中国社区医师. 2025(04): 60-62 .
    8. 侯艺文，刘莹，李竹蓉，陈晨，李振城，刘杨. 环状RNA参与自身免疫性肝炎小鼠肝损伤的相关性分析. 中国组织工程研究. 2024(14): 2152-2158 .
    9. 陈玉春，高春，郑立婷，李斌，张久聪，卢利霞，于晓辉. 性激素和Treg/Th17失衡在自身免疫性肝炎中的作用及研究进展. 胃肠病学和肝病学杂志. 2024(01): 98-101 .
    10. 李琼，田爱平，毛永武，王富春，毛小荣. 抗核抗体谱对AIH-PBC OS及单纯AIH患者激素应答的影响. 解放军医学杂志. 2024(01): 64-69 .
    11. 夏雨艳，曾琼戎，李福建，黎凤炎，李琪，唐利瑕，张国. 肠道微生态与自身免疫性肝炎发生发展的关系. 临床肝胆病杂志. 2024(02): 374-379 . 本站查看
    12. 杨秀英，党小红，姜洋. 泼尼松联合硫唑嘌呤治疗自身免疫性肝炎疗效和安全性的Meta分析. 胃肠病学和肝病学杂志. 2024(02): 141-149 .
    13. 李竹蓉，陈晨，郭地，吕思学，武嘉文，杨娜，刘杨. 茵陈蒿汤对自身免疫性肝炎小鼠肝细胞铁死亡的抑制作用及其机制分析. 临床肝胆病杂志. 2024(03): 502-508 . 本站查看
    14. 王媛媛，朱丽，丁秀婷. 自身免疫性肝炎临床误诊分析. 临床误诊误治. 2024(02): 25-28 .
    15. 韩冰，任建峰，涂传涛. 大麻二酚调控ConA诱导小鼠急性免疫性肝炎巨噬细胞的极化方向. 胃肠病学和肝病学杂志. 2024(03): 257-260 .
    16. 马丽玲，朱启泰，徐俊驰，胥萍，吴敏娟. 肝功能指标与自身抗体指标对自身免疫性肝病鉴别诊断的价值. 抗感染药学. 2024(01): 64-69 .
    17. 魏晓婷，马洪德. 熊去氧胆酸胶囊联合糖皮质激素对自身免疫性肝炎患者肝纤维化指标及免疫功能的影响. 临床医学工程. 2024(05): 597-598 .
    18. 陈杰，周长雄，龚秀敏，郭治. Ⅰ型自身免疫性肝炎患者IL28RA、PD-L1表达及与肝功能的相关性分析. 中国现代医学杂志. 2024(12): 78-83 .
    19. 李慧，张佳庆，赵娜，彭雪莹，赵占娟，王阳阳. Th17和Treg细胞在自身免疫性肝炎发生发展中的作用研究进展. 胃肠病学和肝病学杂志. 2024(05): 618-622 .
    20. 德吉央宗，旺加. 自身免疫性肝病合并干燥综合征一例报道. 西藏医药. 2024(03): 159-160 .
    21. 陈欣欣，张海萍，黄春洋，闫惠平. 有乙型肝炎病毒感染史的自身免疫性肝炎患者的病毒学特征分析. 传染病信息. 2024(01): 5-10 .
    22. 和沁园，岳欣，陈艳. 妊娠早中期合并肝功能异常150例临床分析. 东南大学学报(医学版). 2024(03): 445-450 .
    23. 杨金凤，孙鑫，邢枫，陈高峰，刘坤，刘成海. 中西医结合诊治自身免疫性肝炎肝硬化合并皮肤型结节性多动脉炎1例. 中西医结合肝病杂志. 2024(05): 454-456 .
    24. 李月梅，姚旋，吕瑾，徐静茹. 自身免疫性肝炎患者隐匿性HBV感染流行情况及临床、病毒学特征. 肝脏. 2024(05): 567-570 .
    25. 钟淑勤，莫海兴，邓锦满. 自身免疫性肝炎患者血清miR431-5-p和miR143-3-p表达与病情严重程度的关系研究. 国际检验医学杂志. 2024(13): 1656-1660 .
    26. 蒋瑶，仲伟明，周俏怡，邵宁，吕冰，孙舒. 吗替麦考酚酯治疗难治性自身免疫性肝炎患者疗效初步研究. 实用肝脏病杂志. 2024(04): 539-542 .
    27. 李青，周路艳，谭智，刘灵芝. 自身免疫性肝病患者血清PRDX1、PTEN水平及其与肝功能、疾病活动性的关系. 国际检验医学杂志. 2024(14): 1682-1686 .
    28. 彭雪莹，王阳阳，陈治，张建光，李慧，张佳庆，刘英华. 羟基红花黄色素A对实验性自身免疫性肝炎小鼠的保护作用. 医学研究与教育. 2024(03): 1-7 .
    29. 靳华，汪晓军，赵世娇，王一同. 和血荣肤汤治疗自身免疫性肝病瘙痒症临床观察. 北京中医药. 2024(06): 590-593 .
    30. 苟悦，邢枫，刘成海. 自身免疫性肝炎合并代谢相关脂肪性肝病的中西医结合诊治探讨. 北京中医药. 2024(06): 600-605 .
    31. 中华医学会器官移植学分会，中国医药生物技术协会移植技术分会. 中国肾脏移植受者生育管理指南(2023版). 中华器官移植杂志. 2024(07): 432-450 .
    32. 张明明，刘寰，张冬梅，吴东波，唐红. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征合并肺隐球菌病1例报告. 临床肝胆病杂志. 2024(08): 1666-1669 . 本站查看
    33. 高怡，沈小雪，夏素芹，张洁，朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响. 实用肝脏病杂志. 2024(05): 709-712 .
    34. 李娟，哈小琴，卢利霞. 自身免疫性肝病发病机制的研究进展. 实用临床医药杂志. 2024(17): 137-142 .
    35. 于敏，仲跻凤，季瑜. 实时剪切波弹性成像联合血清IL-6/IL-22水平与自身免疫性肝病肝纤维化的相关性. 肝脏. 2024(08): 919-923 .
    36. 孙超，吴成胜，张彩彩，张玉睿. 白芍总苷联合双环醇治疗轻症自身免疫性肝炎临床观察. 包头医学院学报. 2024(08): 49-54 .
    37. 李艳，冯伟广，郭付全，刘慧敏，孙秀娟. HIV感染合并自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征1例. 中国艾滋病性病. 2024(10): 1082-1084 .
    38. 谢翀，肖影群. 阿托伐他汀诱导的自身免疫样肝炎1例及文献复习. 南昌大学学报(医学版). 2024(05): 103-107 .
    39. 王莉芬，朱金霞，刘光伟. 肠道微生物、Th17细胞和Treg细胞影响自身免疫性肝炎的研究进展. 中西医结合肝病杂志. 2024(10): 948-952 .
    40. 梁燕楼，王子弦，陈杉杉，吴静. 二维剪切波弹性成像在不同类型自身免疫性肝病纤维化分期中的应用. 南通大学学报(医学版). 2024(05): 464-468 .
    41. 中国医疗保健国际交流促进会基层检验技术标准化分会. 基层医疗机构开展自身抗体检测与应用的专家共识. 中华预防医学杂志. 2024(12): 1835-1852 .
    42. 夏淑敏，唐映梅，徐加敏，朱碧莲，李秦念. 13例原发性硬化性胆管炎患者临床特征分析. 肝脏. 2024(11): 1396-1400 .
    43. 陈克岩，吴婷，杨灿. T淋巴细胞线粒体损伤指数在自身免疫性肝炎患者中的临床意义及影响因素. 肝脏. 2024(11): 1409-1412+1426 .
    44. 李晔，李晓松，李梅，李旭艳，王楷，刘兵兵，孟宇. 3种方法学检测抗核抗体谱结果分析. 标记免疫分析与临床. 2024(11): 2036-2040 .
    45. 蒋黎，陈芳，谭朝霞，毛青，夏杰. 艾滋病合并自身免疫性肝炎1例. 中国艾滋病性病. 2023(01): 108-110 .
    46. 王雪鑫，李颖霞，姜利彬，周明霞，魏大鹏，张晓朋，温洪涛. 实时剪切波弹性成像对自身免疫性肝炎纤维化的诊断价值. 临床肝胆病杂志. 2023(01): 97-103 . 本站查看
    47. 胡蓝烁，黄炫淳，杨先照. 基于“厥阴不治，求之阳明”从调木、理土、畅腑论治自身免疫性肝炎. 环球中医药. 2023(01): 111-115 .
    48. 王丽，杨永峰. 自身免疫性肝炎诊治——病理必不可缺. 临床肝胆病杂志. 2023(03): 504-510 . 本站查看
    49. 郝君玉，刘光伟，谢露，范文艳，陈虹秀. 中药有效成分干预自身免疫性肝炎相关信号通路的研究进展. 临床肝胆病杂志. 2023(03): 663-670 . 本站查看
    50. 肿瘤合并肝损伤患者血小板减少症管理中国专家共识（2022版）. 肿瘤防治研究. 2023(03): 211-223 .
    51. 杨秀英，党小红，姜洋. 自身免疫性肝炎的药物治疗进展. 临床肝胆病杂志. 2023(04): 915-921 . 本站查看
    52. 张丽丽，胡建华，王一同，包一珺，吕文良. 基于《理虚元鉴》理论浅探自身免疫性肝炎的防治. 环球中医药. 2023(04): 740-742 .
    53. 甄永利，张亚飞，张振华. 自身免疫性肝病患者甲状腺功能变化及其对治疗应答的影响. 实用肝脏病杂志. 2023(04): 508-511 .
    54. 杨航，赵黎莉，韩萍，陈庆灵，文君，刘洁，程晓静，李嘉. 血清壳多糖酶3样蛋白1(CHI3L1)对肝硬化患者发生失代偿事件风险的预测价值. 临床肝胆病杂志. 2023(07): 1578-1585 . 本站查看
    55. 赵娟，徐斌. 进修医师自身免疫性肝炎临床带教体会. 继续医学教育. 2023(06): 129-132 .
    56. 姚尚娟，李依琳，陈明洁，李强. 自身免疫性肝病重叠综合征的诊断和治疗. 临床肝胆病杂志. 2023(08): 1952-1957 . 本站查看
    57. 王翠，王芬，陈林. 遂宁市中心医院2006～2022年常见非感染性肝病分布特征及变化趋势分析. 现代消化及介入诊疗. 2023(05): 573-577 .
    58. 彭世秀，李春燕，黄爱萍，朱松涛，麦静，伍丽萍. HIV感染合并自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征1例报告. 临床肝胆病杂志. 2023(09): 2175-2178 . 本站查看
    59. 徐志远，杨永峰. 2012-2021年南京市第二医院肝病住院患者疾病谱及变化趋势分析. 临床肝胆病杂志. 2023(09): 2137-2144 . 本站查看
    60. 于航，闫涛，孙耀. 肝病相关血小板减少症临床管理中国专家共识. 临床肝胆病杂志. 2023(10): 2307-2320 . 本站查看
    61. 王楠，张鹏飞，陈丽，谭友文. 1例以肝衰竭为首发表现的IgG4相关疾病患者6年诊治随访. 肝脏. 2023(09): 1138-1140 .
    62. 尹全乐，张红霞，陈旭，周璐，王颖. 自身免疫性肝病患者腹部淋巴结肿大的临床及影像学特征分析. 解放军医学杂志. 2023(10): 1201-1207 .
    63. 叶雯，徐建良，杨妮. 微RNA在自身免疫性肝炎中的研究进展. 中国医药导报. 2023(28): 58-61 .
    64. 王雪，吴宿慧，李寒冰，李根林，徐江雁. 基于中西医临床病证特点的自身免疫性肝炎动物模型分析. 中药药理与临床. 2023(11): 100-103+114 .
    65. 庞雪花，林懋惺，刘宏. 自身免疫性肝炎患者血清生长分化因子15水平变化及其临床意义. 肝脏. 2023(12): 1484-1486+1491 .
    66. 杨月华，蓝婧，姚朝光，黄佳. 临床变量和肝组织学变化对自身免疫性肝炎肝纤维化和肝硬化发展的预后价值. 肝脏. 2023(12): 1487-1491 .
    67. 韦何锐，高美欣，肖凡，魏红山. Glt25d1基因通过调节NKT细胞及Treg细胞比例加重Con A诱导的免疫性肝损伤. 中国肝脏病杂志(电子版). 2023(04): 33-38 .
    68. 韩冰，涂传涛. 特殊临床表型及特殊人群自身免疫性肝炎诊治现状. 中国肝脏病杂志(电子版). 2023(04): 16-21 .
    69. 黄春洋，刘燕敏. 重视不典型自身免疫性肝病患者的早诊早治. 临床肝胆病杂志. 2022(04): 748-753 . 本站查看
    70. 闫惠平，刘燕敏，张海萍. 近二十年我国自身免疫性肝病领域发展历程的回顾与展望. 临床肝胆病杂志. 2022(04): 737-742 . 本站查看
    71. 方峰. 儿童自身免疫性肝炎的诊治难点与对策. 中国实用儿科杂志. 2022(07): 493-495 .
    72. 文倩，张庆，李双庆. 药物性重度肝损伤1例报告并文献复习. 中华全科医师杂志. 2022(08): 764-766 .
    73. 李春燕，徐文娇，邵利梅，汤善宏. 自身免疫性肝炎在孕前-妊娠-产后期的管理. 临床肝胆病杂志. 2022(08): 1892-1895 . 本站查看
    74. 段维佳，吕婷婷，陈莎，王倩怡，王晓明，王宇，欧晓娟，李淑香. 抗线粒体抗体阳性的自身免疫性肝炎患者的临床特点及预后. 临床和实验医学杂志. 2022(18): 1931-1934 .
    75. 蔡静，周桂琴，刘亚兴，李斌，王晓静，冯颖，王宪波. 首乌制剂相关肝损伤伴或不伴自身抗体阳性患者临床特征比较. 临床肝胆病杂志. 2022(10): 2296-2301 . 本站查看
    76. 周梦婷，韩红梅. 自身免疫性肝炎不典型发作1例报告. 临床肝胆病杂志. 2022(11): 2565-2567 . 本站查看
    77. 宁会彬，李宽，彭真，刘晖，马雄，赵鸿，尚佳. 药物性肝损伤合并吉尔伯特综合征治疗中继发肺孢子菌及巨细胞病毒混合感染1例. 中华传染病杂志. 2022(11): 699-701 .
    78. 王璇，赵艳超，吴璇，张贺媛. 个体化护理干预对自身免疫性肝炎患者临床指标及心理状态的影响. 北京医学. 2022(10): 953-955+957 .
    79. 林秋香，李圣聪，林爱芳，黄祖雄. 自身免疫抗体谱及抗核抗体核型检测在自身免疫性肝病中的诊断价值. 热带医学杂志. 2022(11): 1507-1510 .
    80. 高媛娇，林妍洁，杨柳，毕潇月，邓雯，蒋婷婷，孙芳芳，路遥，张璐，李明慧，谢尧. 不同抗体状态的自身免疫性肝炎肝脏组织病理学与临床特征的比较. 临床肝胆病杂志. 2022(12): 2744-2749 . 本站查看

    Other cited types(34)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article has an altmetric score of 7
    Article views (6667) PDF downloads(1915) Cited by(114)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2346]YesterdayPV[4902]TodayIP[66]TodayPV[132]Online[24]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return